Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Alzheimer’s Disease Research Update

2/19/2018

 
The first part of 2018 has not seen positive developments in the search for new treatments for Alzheimer’s Disease. Merck recently announced the discontinuation of the verubecestat Phase III APECS trial when an interim analysis failed to demonstrate a benefit in patients with prodromal Alzheimer's Disease. The EPOCH trial was also terminated early when verubecestat failed to demonstrate a benefit in patients with mild to moderate disease.  In both large trials, verubecestat lowered levels of beta-amyloid, but failed to improve symptoms or prevent progression of Alzheimer’s Disease.

Two other drug in development for the treatment of Alzheimer’s Disease were also recently in the news. Biogen announced that enrollment in two Phase III studies of aducanumab (ENGAGE and EMERGE) will be increased by 255 patients each due to variability of the primary endpoint.  Earlier this month Boehringer discontinued development of BI 409306 after the drug failed to demonstrate a benefit in two Phase II trials. 

These three drugs work by different mechanisms. Verubecestat inhibits Beta-secretase (BACE), which prevents the formation of beta amyloid.  Aducanumab is a monoclonal antibody that reduces amyloid beta by binding to the protein.  BI 409306 blocks phosphodiesterase 9A (PDE 9A), which improves signaling in the glutamatergic circuit of the brain. So do we need to look at different targets to prevent to treat Alzheimer’s Disease or do we need a new strategy?

It has been debated whether potential treatments would be more effective if used before development of symptoms in Alzheimer's Disease.  Studies in early stages of the disease have not been successful, so the drugs may need to be tested in patients at risk of developing the disease. To address this issue, the FDA has proposed that if reliable biomarkers can be developed to diagnose Alzheimer’s before the onset of subtle cognitive or functional changes, these biomarkers could be used as surrogate endpoints for the approval of a new drug.  Since there are no accepted biomarkers for Alzheimer’s Disease, the FDA has encouraged researchers to develop them.

There are two drugs being studied in trials with patient populations without any cognitive or functional changes.  Amgen and Novartis are developing CNP520 and J&J is developing JNJ-54861911.  Both drugs are Beta Secretase (BACE) Inhibitors.  They are being studied in long term trials of patients without symptoms that carry the APOE4 gene.  Both studies are currently forecast to be completed in 2024 and have patient populations of over 1,500 patients.  The APOE4 gene is being used as a biomarker to predict patients at risk of developing Alzheimer’s.  Additional biomarkers are needed to predict the actual development or progression of disease. 

I reviewed drugs in development for the treatment of Alzheimer’s Disease in the December issue of Hospital Pharmacy last year. 

You can review up-to-date information on Alzheimer’s drugs with the Prescribe Right Pharmaceutical Pipeline Tracker. 

Providing Comprehensive Medication Management in Telehealth

2/1/2018

 
The goal of this white paper is to provide direction for clinical pharmacists providing telehealth. Telehealth care is rapidly emerging to improve patient access to health care and optimize patient health outcomes. With the increasing ability to access electronic health record portals, as many as 75 million telehealth encounters are expected in North America annually. Although electronic “point of access” undoubtedly increases the use of medical and pharmacy services, the real value of telehealth lies in improved access to patients in remote areas lacking adequate medical and pharmacy services and to high-risk patients requiring frequent monitoring. This document is intended to serve as a guide for those interested in or already using telehealth to provide direct patient care. Specifically, it focuses on general concepts of telehealth and demonstrates how the delivery of comprehensive medication management (CMM) by telehealth aligns with the Standards of Practice for Clinical Pharmacists set forth by the American College of Clinical Pharmacy. Although clinical pharmacists must be appropriately credentialed and privileged to provide CMM, their process of care must also be adapted to suit the remote patient. Patient assessment, evaluation of medication therapy, development and implementation of a plan of care, follow-up, monitoring, and documentation of all processes of care are influenced by the technology available, the collaborations established, and the applicable regulations and requirements for telehealth practice.

You can access the paper on the Pharmacotherapy website
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.